Zoetis Stock Tumbles to 52-Week Low as Pet Segment Drags Down Earnings and Outlook

Zoetis shares hit a 52-week low as Q1 earnings miss and slashed guidance erase $16B in market cap, with pet-care sales declining and generic competition rising.

The sell-off in Zoetis shares accelerated this week, pushing the animal health giant to a fresh 52-week low of €63.76 intraday on Wednesday. That marks a staggering €16 billion evaporation in market capitalisation over the past seven trading days alone, as investors recoil from a double earnings miss and a slashed full-year forecast.

Revenue for the first quarter inched up nearly 2% to $2.26 billion, yet organic growth stalled flat. Adjusted earnings per share of $1.53 came in well below analyst expectations. The real pain, however, lies in the company’s product mix. Operating margin shrank from 38.4% to 36.3%, squeezed by a shift away from high-margin pet-care drugs toward cheaper livestock medicines.

The pet business, historically Zoetis’s growth engine, saw sales crater 11% in the United States. Dog and cat owners are visiting veterinarians less often and switching to more affordable options. Regulatory filings also point to rising generic competition, particularly against established blockbusters such as the antibiotic Convenia and the anti-nausea drug Cerenia, as key patents expire.

Livestock revenue proved a bright spot, climbing 12% organically and generating a steady $720 million per quarter. International sales also posted double-digit gains. But these bright spots were insufficient to offset the drag from the companion-animal division, leaving the overall top line flat on an organic basis.

Management responded by scaling back its ambitions. Zoetis now guides for full-year 2026 revenue in a range of $9.68 billion to $9.96 billion — the midpoint of $9.82 billion is roughly in line with the reduced consensus. Adjusted earnings per share are now expected to peak at $7.00, a downward revision that reflects higher price sensitivity among pet owners and intensifying competition in dermatology and parasiticide markets.

The stock has lost nearly a third of its value in the past week alone and has more than halved over the past twelve months. Wall Street remains cautious: the average analyst rating is “hold,” with a median price target near $141, though several banks have cut their targets sharply. UBS lowered its to $99, while Stifel now sees fair value at $105. On the other hand, board member Michael McCallister recently purchased a substantial block of shares just before the latest rout, signalling internal confidence.

Zoetis is banking on a pipeline refresh to restore momentum. The upcoming approval of a new formulation of the dermatology drug Cytopoint could provide a near-term catalyst, but until that materialises, the headwinds from generics and belt-tightening pet owners look set to persist.